A. Raja, J. Lebbos, P. Kirkpatrick
2003
Citations
0
Influential Citations
20
Citations
Journal
Nature Reviews Drug Discovery
Abstract
In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents. Will its favourable dosing schedule and side-effect profile lead to success in this crowded and complex market?